Asia Pacific Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The Asia Pacific human microbiome market is projected to grow significantly, reaching approximately US$ 703.84 million by 2031, up from US$ 124.10 million in 2023, reflecting a robust compound annual growth rate (CAGR) of 24.2% during this period.

Executive Summary and Market Analysis

The market is divided into several regions, including Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Key drivers of growth in this market include the rising prevalence of metabolic disorders, an increasing demand for research in gene mutation and drug development, and strategic collaborations among market participants. Additionally, government initiatives and funding aimed at enhancing awareness of the human microbiome are further propelling market expansion.

Market Segmentation

The Asia Pacific human microbiome market can be analyzed through various segments, including type, application, and disease type.

Type: The market is categorized into products and software/services, with the product segment dominating in 2023. This segment is further divided into probiotics and prebiotics.
Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
Disease Type: The market is also segmented by disease type, including obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with the GIT segment leading in market share in 2023.

Market Outlook

The human microbiome's potential to revolutionize healthcare has led to a surge in investments in research and development. The microbiome, consisting of trillions of microorganisms residing in and on the human body, plays a crucial role in maintaining health and preventing diseases. Biotech startups and pharmaceutical companies are increasingly funding the development of microbiome-based therapies. For instance, Xome Life Sciences, one of India's pioneering microbiome startups, is focused on creating diagnostic and therapeutic tools that leverage microbiome data to enhance health outcomes.

Moreover, Seres Therapeutics has received FDA approval for a treatment targeting recurrent Clostridium difficile infections, showcasing the therapeutic potential of microbiome-based drugs. Companies like Vedanta Biosciences are also raising significant funds to develop immunotherapies derived from microbiomes for conditions such as autoimmune disorders and cancer. Notable investors, including Seventure Partners and Flagship Pioneering, are actively supporting companies that analyze microbiome data, highlighting the growing recognition of the microbiome's importance in health. This influx of investment is expected to drive advancements in precision medicine and therapeutic interventions, creating numerous opportunities within the market.

Country Insights

The Asia Pacific human microbiome market includes key countries such as China, Japan, India, Australia, South Korea, and others, with China holding the largest market share in 2023. Factors such as new pharmaceutical developments, product enhancements, and strategic partnerships are significantly benefiting the microbiome therapies market in China. For example, Xbiome Inc., an AI-driven microbiome therapeutics company, has acquired a clinical-stage program from Assembly Biosciences, which is focused on innovative treatments for viral disorders like hepatitis B.

The increasing prevalence of target disorders is expected to further stimulate growth in the human microbiome market. Research continues to uncover the microbiome's critical role in various health conditions, leading to a heightened interest in microbiome-based therapies, particularly for gastrointestinal disorders, autoimmune diseases, and metabolic disorders. The potential for microbiome therapeutics to offer more effective and personalized treatment options presents a promising avenue for market growth. According to the National Institute of Health, the prevalence of Irritable Bowel Syndrome (IBS) in China ranges from 2.3% to 15.8%, indicating a significant market opportunity.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase market share.

Product Code: TIPRE00003317

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Asia Pacific Human Microbiome Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Significant Investments by Key Market Players
- 4.1.2 Government Initiatives
4.2 Market Restraints
- 4.2.1 Challenges During Production of Microbiome
4.3 Market Opportunities
- 4.3.1 Robust Investment in Research and Development
4.4 Future Trends
- 4.4.1 Emergence of Precision Medicine
4.5 Impact of Drivers and Restraints:

5. Human Microbiome Market - Asia Pacific Analysis

5.1 Asia Pacific Human Microbiome Market Revenue (US$ Million), 2021-2031
5.2 Asia Pacific Human Microbiome Market Forecast Analysis

6. Asia Pacific Human Microbiome Market Analysis - by Type

6.1 Product
- 6.1.1 Overview
- 6.1.2 Product: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Software and Services: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Human Microbiome Market Analysis - by Application

7.1 Therapeutics
- 7.1.1 Overview
- 7.1.2 Therapeutics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Diagnostics
- 7.2.1 Overview
- 7.2.2 Diagnostics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Human Microbiome Market Analysis - by Disease Type

8.1 Obesity
- 8.1.1 Overview
- 8.1.2 Obesity: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diabetes
- 8.2.1 Overview
- 8.2.2 Diabetes: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Autoimmune Disorder
- 8.3.1 Overview
- 8.3.2 Autoimmune Disorder: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Cancer
- 8.4.1 Overview
- 8.4.2 Cancer: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.5 GIT
- 8.5.1 Overview
- 8.5.2 GIT: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Human Microbiome Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Human Microbiome Market Overview
- 9.1.2 Asia Pacific Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.1 Asia Pacific Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.2 China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.2.1 China: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.2.2 China: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.2.3 China: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.2.4 China: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.3 Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.3.1 Japan: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.3.2 Japan: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.3.3 Japan: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.3.4 Japan: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.4 India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.4.1 India: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.4.2 India: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.4.3 India: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.4.4 India: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.5 Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.5.1 Australia: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.5.2 Australia: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.5.3 Australia: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.5.4 Australia: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.6 South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.6.1 South Korea: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.6.2 South Korea: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.6.3 South Korea: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.6.4 South Korea: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.7 Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.7.1 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.7.2 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.7.3 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.7.4 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Disease Type

10. Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Human Microbiome Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 MaaT Pharma
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Ferring Holdings SA
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 AOBiome Therapeutics Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Finch Therapeutics Group Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Financial Overview
- 11.4.4 SWOT Analysis
- 11.4.5 Key Developments
11.5 Seres Therapeutics Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Merck & Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Yakult Honsha Co., Ltd.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Rebiotix, Inc.
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 IFF Nutrition & Biosciences
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Synthetic Biologics, Inc.
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 Glossary of Terms
12.2 About The Insight Partners